As survivin is a potential downstream target of JAK2/STAT3 pathway (Scheper et al, 2007; Glienke et al, 2010), we further explored whether Cuc IIa also inhibited cancer cell expansion by inhibiting JAK2/STAT3 activation. Here, BIRC5 is linked to cancer.